Evidence map›Paper›PMID 25938513›Full record

ArticlePloS one2015

High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions.

Sophie Bernichtein, Natascha Pigat, Thierry Capiod, Florence Boutillon, Virginie Verkarre, Philippe Camparo, Mélanie Viltard, Arnaud Méjean, Stéphane Oudard, Jean-Claude Souberbielle and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Influence of Diet and Nutrition on Prostate Cancer.International journal of molecular sciences · 2020
    Review
  5. Article
  6. Review
  7. CombinedFrontiers in pharmacology · 2019
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sophie BernichteinInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Natascha PigatInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Thierry CapiodInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Florence BoutillonInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Virginie VerkarrePathology Department, Hôpital Necker, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France.
Philippe CamparoInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Mélanie ViltardInstitute for European Expertise in Physiology, Paris, France.
Arnaud MéjeanUrology Department, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France.
Stéphane OudardMedical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France.
Jean-Claude SouberbielleInserm, U1151, Institut Necker Enfants Malades, Phosphate Homeostasis Laboratory, Paris, France; Physiology Department, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France.
Gérard FriedlanderInserm, U1151, Institut Necker Enfants Malades, Phosphate Homeostasis Laboratory, Paris, France; Physiology Department, Hôpital Européen Georges Pompidou, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France.
Vincent GoffinInserm, U1151, Institut Necker Enfants Malades, PRL/GH Pathophysiology Laboratory, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
Université Paris Cité · FRSorbonne Paris Cité · FRInstitut Necker Enfants Malades · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological studies that have investigated whether dairy (mainly milk) diets are associated with prostate cancer risk have led to controversial conclusions. In addition, no existing study clearly evaluated the effects of dairy/milk diets on prostate tumor progression, which is clinically highly relevant in view of the millions of men presenting with prostate pathologies worldwide, including benign prostate hyperplasia (BPH) or high-grade prostatic intraepithelial neoplasia (HGPIN). We report here a unique interventional animal study to address this issue. We used two mouse models of fully penetrant genetically-induced prostate tumorigenesis that were investigated at the stages of benign hyperplasia (probasin-Prl mice, Pb-Prl) or pre-cancerous PIN lesions (KIMAP mice). Mice were fed high milk diets (skim or whole) for 15 to 27 weeks of time depending on the kinetics of prostate tumor development in each model. Prostate tumor progression was assessed by tissue histopathology examination, epithelial proliferation, stromal inflammation and fibrosis, tumor invasiveness potency and expression of various tumor markers relevant for each model (c-Fes, Gprc6a, activated Stat5 and p63). Our results show that high milk consumption (either skim or whole) did not promote progression of existing prostate tumors when assessed at early stages of tumorigenesis (hyperplasia and neoplasia). For some parameters, and depending on milk type, milk regimen could even exhibit slight protective effects towards prostate tumor progression by decreasing the expression of tumor-related markers like Ki-67 and Gprc6a. In conclusion, our study suggests that regular milk consumption should not be considered detrimental for patients presenting with early-stage prostate tumors.

Indexed as

Disease ProgressionAnimalsBiomarkers, TumorCell ProliferationDietDisease Models, AnimalFibrosisHypertrophyInflammationMaleMiceMilkNeoplasm InvasivenessOrgan SizeProstateProstatic NeoplasmsBiomarkers, Tumor

Identifiers

PMID25938513
PMCPMC4418739
OpenAlexW279537528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.